Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
China
Enrollment target
~241 participants
Started
April 2024
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2026.